What Is ARA-290 10mg?

ARA-290 10mg is a non-erythropoietic peptide designed to selectively interact with the tissue-protective receptor, also referred to as the innate repair receptor. This receptor complex consists of CD131 paired with a component of the erythropoietin receptor. By targeting this receptor, ARA-290 allows researchers to investigate cellular repair, inflammatory modulation, and pain-related signaling without activating hematopoietic pathways.

ARA-290 10mg is an experimental research compound and is not approved for human or animal use.

Research Background

Erythropoietin is known for its role in erythropoiesis, but research has identified additional domains responsible for tissue protection and cellular repair. ARA-290 was developed by isolating and modifying this protective region to retain regenerative signaling while eliminating red blood cell stimulation.

Preclinical studies have explored ARA-290 in models related to neuropathic pain, inflammatory regulation, vascular protection, and neural repair signaling. Research has focused on its interaction with non-hematopoietic receptors involved in innate repair mechanisms. All findings remain preclinical.

Mechanisms of Research Interest

Innate Repair Receptor Activation

ARA-290 10mg has been studied for its ability to bind the tissue-protective receptor, initiating signaling cascades associated with cellular repair, survival, and inflammation modulation.

Nociceptive Pathway Research

Experimental models suggest ARA-290 may influence nociception-related signaling, including modulation of transient receptor potential vanilloid 1 channels, which are involved in pain sensitivity and inflammatory responses.

Anti-Inflammatory Signaling

Research indicates potential involvement in reducing expression of pro-inflammatory cytokines, including interleukin 1 beta and tumor necrosis factor alpha, in laboratory inflammation models.

Vascular and Endothelial Research

ARA-290 has been examined for its potential role in endothelial cell protection and vascular repair signaling, particularly in ischemia-related experimental systems.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Molecular and Chemical Information

• Product Name: ARA-290 10mg

• Form: Lyophilized powder

• Purity: Greater than 99%

• Peptide Length: 11 amino acids

• Classification: Non-erythropoietic erythropoietin-derived peptide

• Molecular Formula: C51H54N16O21

• Molecular Weight: 1257.3 g/mol

• Alternate Names: Cibinetide, helix B surface peptide, PH-BSP

Research Applications

ARA-290 10mg may be utilized by qualified researchers in laboratory investigations involving:

• Tissue repair and regenerative signaling research

• Neuropathic and nociceptive pathway studies

• Inflammatory cytokine and immune response models

• Vascular protection and endothelial repair research

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data